GVK BIO has announced an extended collaboration with the Melbourne, Australia-based clinical stage biopharmaceutical company, Akaal Pharma Pvt Ltd, for the scale-up of its novel topical AKP-11 ointment to support Phase-II clinical studies in psoriasis.
The Hyderabad-based company's formulation development business unit in Bengaluru has developed a scalable process for the ointment. GVK BIO plans to support clinical studies of Akaal Pharma’s topical psoriasis drug by providing clinical supplies, manufacturing, and analytical support.
Discussions are also ongoing to work towards exploring appropriate commercialization packaging and various formulations for topical use in other inflammatory diseases, said Seetharaju Gembali, Senior Vice-President, Formulation R&D of GVK BIO,
Expressing confidence in the collaboration, Dale Dhanoa, CEO of Akaal Pharma, said: “There are several other inflammatory diseases that we are targeting with our clinical compounds and are currently exploring various formulations for its topical applications.”
No comments:
Post a Comment